In animal models, dihydroartemisinin outperformed cisplatin by enhancing body mass and substantially decreasing serum TNF-α concentrations, tumor mass, and volumetric dimensions with 41.45% tumor growth inhibition. This evidence concerns the gene TNF and neoplasm.